Effects of omalizumab on markers of inflammation in patients with allergic asthma von Holgate, S, Smith, N, Massanari, M, Jimenez, P

Volltext

Effect of omalizumab on peripheral blood eosinophilia in allergic asthma von Massanari, M, Holgate, S.T, Busse, W.W, Jimenez, P, Kianifard, F, Zeldin, R

Volltext

P318 Impact of feno on treatment decisions: results from the ASTH2MA (assessment of TH2 inflammation) survey von Hanania, N, Massanari, M, Peddicord, T, Kassel, E, LaForce, C, Rickard, K

Volltext

Omalizumab (Xolair) May Normalize IgE Production Rate In Patients With Moderate-To-Severe Atopic Asthma von Lowe, P, Tannenbaum, S, Gautier, A, Massanari, M, Panahloo, Z

Volltext

Effect of Omalizumab on Asthma Control and Quality of Life in Patients with Moderate-Severe Persistent IgE-Mediated Asthma and Allergy to House Dust Mite von Maykut, R, Massanari, M, Kianifard, F, Zeldin, R

Volltext

P402 Cost-effectiveness of exhaled nitric oxide (feno) monitoring in asthma management von Massanari, M., Aja, D., Brooks, E.

Volltext

Eligibility for Omalizumab Dosing in Children and Young Adults Based on IgE and Body Weight von Sorkness, C.A, Curry, M.D, Massanari, M, Wildfire, J

Volltext

Association Between Recent and Future Asthma Exacerbations in Pediatric Patients With Severe or Difficult-to-Treat Asthma von Fish, J.E, Haselkorn, T, Mink, D.R, Massanari, M

Volltext

Addition of Omalizumab Improved Functional Health Status in Patients With Impaired Quality of Life Associated With Moderate-Severe Persistent Allergic Asthma von Massanari, M, Sacco, P, Kianifard, F, Maykut, R, Zeldin, R

Volltext

Characteristics and Outcomes of Asthmatics Who Leave Against Medical Advice (AMA) von Baptist, A.P, Ager, J, Massanari, M

Volltext

Adding Omalizumab to the Therapy of Adolescents With Persistent Uncontrolled Moderate—Severe Allergic Asthma von Massanari, M., Milgrom, H., Pollard, S., Maykut, R.J., Kianifard, Farid, Fowler-Taylor, A., Geba, G.P., Zeldin, R.K.

Volltext

Addition of Omalizumab Improves Quality of Life in Moderate-Severe Asthmatics Receiving Fluticasone 500 μg/Salmeterol 50 μg von Massanari, M, Maykut, R.J, Kianifard, F, Zeldin, R.K, Geba, G.P

Volltext

Treatment Patterns and Asthma Control Among US Allergy and Pulmonary Community Practices: Results of the CHARIOT Study von Marcus, P, Arnold, R.J.G, Ekins, S, Sacco, P, Massanari, M, Donohue, J, Bukstein, D

Volltext

Assessment of the Psychometric Properties of the Paediatric Asthma Quality of Life Questionnaire (PAQLQ) in Moderate to Severe Pediatric Asthma Patients von Lobo, F.S, Revicki, D, Grant, W, Turk, F, Massanari, M

Volltext

Paradoxical Reactions in Children Associated with Midazolam Use During Endoscopy von Massanari, Marc, Novitsky, Janie, Reinstein, L. Julio

Volltext

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians von Kinzie, J. L., Naylor, P. H., Nathani, M. G., Peleman, R. R., Ehrinpreis, M. N., Lybik, M., Turner, J. R., Janisse, J. J., Massanari, M., Mutchnick, M. G.

Volltext

In Moderate-Severe Asthma, Omalizumab Reduced the Need for Rescue Systemic Steroid Bursts and Improved Ratings of Treatment Effectiveness: A Pooled Analysis von Maykut, R., Massanari, M., Zeldin, R., Kianifard, F., Deniz, Y., Reisner, C., Geba, G.

Volltext

Addition of Omalizumab Reduces School Absenteeism in Children with Moderate-Severe Persistent Asthma von Milgrom, H, Massanari, M, Maykut, R.J, Kianifard, F, Zeldin, R.K, Geba, G.P

Volltext

Effect of Omalizumab on Measures of Control in Adolescents with Moderate-Severe Persistent Asthma von Pollard, S.J, Maykut, R.J, Massanari, M, Kianifard, F, Zeldin, R.K, Geba, G.P

Volltext

Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma von Brooks, Elizabeth A, Massanari, Marc, Hanania, Nicola A, Weiner, Daniel J

Volltext